Stock Research for OREX


Featured Broker: Ally Invest

Get the due diligence for another stock.


OREX Stock Chart & Research Data

The OREX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OREX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


OREX Due diligence Resources & Stock Charts

The OREX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View OREX Detailed Price Forecast - CNN Money CNN View OREX Detailed Summary - Google Finance
Yahoo View OREX Detailed Summary - Yahoo! Finance Zacks View OREX Stock Research & Analysis -

Stock Analysis

TradeIdeas View OREX Trends & Analysis - Trade-Ideas Barrons View OREX Major Holders - Barrons
NASDAQ View OREX Call Transcripts - NASDAQ Seeking View OREX Breaking News & Analysis - Seeking Alpha
Spotlight View OREX Annual Report - OTC Report View OREX OTC Short Report -
TradeKing View OREX Fundamentals - TradeKing Charts View OREX SEC Filings - Bar Chart
WSJ View Historical Prices for OREX - The WSJ Morningstar View Performance/Total Return for OREX - Morningstar
MarketWatch View the Analyst Estimates for OREX - MarketWatch CNBC View the Earnings History for OREX - CNBC
StockMarketWatch View the OREX Earnings - StockMarketWatch MacroAxis View OREX Buy or Sell Recommendations - MacroAxis
Bullish View the OREX Bullish Patterns - American Bulls Short Pains View OREX Short Pain Metrics -

Social Media Mentions

StockTwits View OREX Stock Mentions - StockTwits PennyStocks View OREX Stock Mentions - PennyStockTweets
Twitter View OREX Stock Mentions - Twitter Invest Hub View OREX Investment Forum News - Investor Hub
Yahoo View OREX Stock Mentions - Yahoo! Message Board Seeking Alpha View OREX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for OREX - Insider Cow View Insider Transactions for OREX - Insider Cow
CNBC View OREX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for OREX - OTC Markets
Yahoo View Insider Transactions for OREX - Yahoo! Finance NASDAQ View Institutional Holdings for OREX - NASDAQ

Stock Charts

FinViz View OREX Stock Insight & Charts - StockCharts View OREX Investment Charts -
BarChart View OREX Stock Overview & Charts - BarChart Trading View View OREX User Generated Charts - Trading View

Latest Financial News for OREX

[$$] Firm Retention Summary: Orexigen Therapeutics Inc.
Posted on Thursday May 10, 2018

This is a summary of a request from the official committee of unsecured creditors of Orexigen Therapeutics Inc. to hire Irell & Manella LLP as counsel, filed April 27 with the U.S. Bankruptcy Court in ...

[$$] Pernix, Investor Group Offer $75 Million for Orexigen
Posted on Monday April 23, 2018

The offer, revealed Monday in a filing in U.S. Bankruptcy Court in Wilmington, Del., is subject to higher bids at a court-supervised auction. The deal would include the world-wide rights to anti-obesity drug Contrave. to name the investor group’s acquisition vehicle, Nalpropion Pharmaceuticals Inc., as the stalking horse, or lead bidder, at the auction.

Orexigen Therapeutics, Inc. Enters Agreement for Sale of Company
Posted on Monday April 23, 2018

SAN DIEGO, April 23, 2018 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to sell substantially all of the assets of the company, subject to court approval.  Under the terms of the agreement, Orexigen will sell the world-wide rights to Contrave® (naltrexone HCl / bupropion HCl extended release) /Mysimba™ (naltrexone HCl and bupropion HCl prolonged release) and certain other Orexigen assets for $75 million in cash. The deal is subject to higher and better offers.

This Obesity Drugmaker Just Made a Comeback While Another Declared Bankruptcy
Posted on Monday March 26, 2018

It's all about the pipeline.

Enter a stock symbol to view the stock details.